Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
|Slideshows|November 18, 2016
Top Prostate Cancer News of 2016
Author(s)Cancer Network Editors
This slide show highlights some of the top prostate cancer news of 2016, including studies on aspirin use and cancer risk, the increased incidence of colorectal tumors in prostate cancer patients, hormone therapy and a link to depression, and more.
Advertisement
Advertisement
Related to this article
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
3
Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC
4
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
5